Personalis rises as blood test detects lung cancer months before imaging

** Shares of U.S.-based cancer diagnostics firm Personalis PSNL rise 3.7% to $8.53

** Co says that new findings from a major AstraZeneca AZN lung cancer trial show its blood test can help track how well patients respond to treatment

** The trial involved patients with advanced lung cancer who received chemoradiation followed by AstraZeneca's drug osimertinib - PSNL

** PSNL's test, called NeXT Personal, looks for tiny traces of cancer DNA in the blood

** PSNL says its test spotted signs of cancer returning about 5 months before standard imaging methods

** Test showed most patients who had signs of cancer DNA after initial treatment saw those signs disappear after taking AZN's osimertinib

** "This study shows how our test can closely track how patients respond to treatment," says Richard Chen, PSNL's medical chief

** Including session moves, stock up ~48% YTD